AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9429755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low antenatal attachment
Number of subjects: 238
Study 9429755 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood states and lack of social support during pregnancy
Number of subjects: 238
Study 8430630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 20
Study 8430630 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 20
Study 3323353 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time B mode ultrasound imaging (USI)
Number of subjects: 430
Study 3323353 — intervention group
Group type: COMPARATOR
Intervention: Bilateral contrast ascending venography
Number of subjects: 430
Study 29406607 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (LFS)
Number of subjects: 278
Study 29406607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea (SU)
Number of subjects: 278
Study 29406607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 278
Study 28073964 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg tenofovir disoproxil fumarate/400 mg emtricitabine
Number of subjects: 12
Study 26235929 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-large pericardial effusion (PE) detected by cardiac magnetic resonance (CMR)
Number of subjects: 780
Study 26235929 — intervention group
Group type: COMPARATOR
Intervention: No intervention specified for control group
Number of subjects: 780
Study 24117234 — intervention group
Group type: EXPERIMENTAL
Intervention: R-HCVAD/R-MA
Number of subjects: 59
Study 24117234 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 59
Study 21372246 — intervention group
Group type: EXPERIMENTAL
Intervention: ReJoyce ET
Number of subjects: 9
Study 21372246 — intervention group
Group type: COMPARATOR
Intervention: Conventional ET
Number of subjects: 9
Study 18309452 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone (HC) replacement therapy on the day of surgery, tapered off thereafter
Number of subjects: 37
Study 18309452 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 37
Study 18309452 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone (HC) replacement therapy
Number of subjects: 37
Study 16540883 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg bid for 16 weeks
Number of subjects: 390
Study 16540883 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir 500 mg qd for 16 weeks
Number of subjects: 390
Study 16540883 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg bid for 10 weeks
Number of subjects: 390
Study 16540883 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir 500 mg qd for 10 weeks
Number of subjects: 390
Study 12749505 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 526
Study 12749505 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily for 10 days
Number of subjects: 526
Study 10895108 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol-supplemented MCT/LCT/omega-3-acid triglycerides (MLF, 5/4/1 w/w/w, 20%) emulsion
Number of subjects: 33
Study 10895108 — intervention group
Group type: COMPARATOR
Intervention: soybean oil-based LCT emulsion (20%)
Number of subjects: 33
Study 8938284 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 8938284 — intervention group
Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 0
Study 29452031 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional spinal immobilization (TSI)
Number of subjects: 20
Study 29452031 — intervention group
Group type: COMPARATOR
Intervention: Spinal motion restriction (SMR)
Number of subjects: 20
Study 28488729 — intervention group
Group type: EXPERIMENTAL
Intervention: C-seal
Number of subjects: 402
Study 28488729 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 402
Study 25857597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 749
Study 25857597 — intervention group
Group type: COMPARATOR
Intervention: Doppler
Number of subjects: 749
Study 25857597 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 749
Study 23934773 — intervention group
Group type: EXPERIMENTAL
Intervention: high MUFA diet (38% E from fat, 20% E as MUFA)
Number of subjects: 39
Study 23934773 — intervention group
Group type: EXPERIMENTAL
Intervention: low-fat, high-complex carbohydrate diet (28% E from fat)
Number of subjects: 39
Study 23934773 — intervention group
Group type: EXPERIMENTAL
Intervention: low-fat, high-complex carbohydrate diet supplemented with 1.24 g/day of long-chain n-3 PUFA
Number of subjects: 39
Study 23934773 — intervention group
Group type: EXPERIMENTAL
Intervention: fat challenge reflecting the same fatty acid composition as the original diets
Number of subjects: 39
Study 23934773 — intervention group
Group type: COMPARATOR
Intervention: different types of diets
Number of subjects: 39
Study 21946315 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 198
Study 21946315 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 198
Study 19454562 — intervention group
Group type: EXPERIMENTAL
Intervention: On-Pump Group (using CPB)
Number of subjects: 40
Study 19454562 — intervention group
Group type: COMPARATOR
Intervention: Off-Pump Group (without CPB)
Number of subjects: 40
Study 19454562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 16231256 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 277
Study 16231256 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate
Number of subjects: 277
Study 16231256 — intervention group
Group type: COMPARATOR
Intervention: Other Licensed Antifungal Therapies (OLAT) after amphotericin B deoxycholate
Number of subjects: 277
Study 16231256 — intervention group
Group type: COMPARATOR
Intervention: Salvage therapy with lipid formulation of amphotericin B after initial treatment with amphotericin B deoxycholate
Number of subjects: 277
Study 12528605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 865
Study 12528605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study 10331750 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular training group (n=8)
Number of subjects: 24
Study 10331750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level training group (n=8)
Number of subjects: 24
Study 10331750 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 24
Study 8952582 — intervention group
Group type: COMPARATOR
Intervention: Valsalva maneuver
Number of subjects: 54
Study 8952582 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 54
Study 8952582 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 54
Study 1941028 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent A (n = 52)
Number of subjects: 100
Study 1941028 — intervention group
Group type: COMPARATOR
Intervention: Consent B (n = 48)
Number of subjects: 100
Study 1941028 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients citing quantitative information
Number of subjects: 100
Study 1941028 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not citing quantitative information
Number of subjects: 100
Study 1941028 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with minimal or severe symptoms
Number of subjects: 100
Study 6179976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of chlorpheniramine maleate and ranitidine hydrochloride
Number of subjects: 25
Study 6179976 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate alone
Number of subjects: 25
Study 6179976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride alone
Number of subjects: 25
Study 31272111 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training with blood flow restriction (BFR‐W)
Number of subjects: 21
Study 31272111 — intervention group
Group type: COMPARATOR
Intervention: Walking training without blood flow restriction (NOR‐W)
Number of subjects: 21
Study 27889667 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 cmH2O PRM
Number of subjects: 90
Study 27889667 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 cmH2O PRM
Number of subjects: 90
Study 27889667 — intervention group
Group type: COMPARATOR
Intervention: Control (passive exsufflation)
Number of subjects: 90
Study 26305390 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) using the GlucoDay(®)S device
Number of subjects: 35
Study 26305390 — intervention group
Group type: COMPARATOR
Intervention: Blinded continuous glucose monitoring (Control)
Number of subjects: 35
Study 26305390 — intervention group
Group type: COMPARATOR
Intervention: Both RT-CGM and Control
Number of subjects: 35
Study 24411758 — intervention group
Group type: EXPERIMENTAL
Intervention: Acutely ill AN participants
Number of subjects: 3
Study 24411758 — intervention group
Group type: COMPARATOR
Intervention: Recovered participants
Number of subjects: 3
Study 24411758 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit affective patterns
Number of subjects: 3
Study 22066898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cones
Number of subjects: 45
Study 22066898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 45
Study 22066898 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study 22066898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cones and PFMT
Number of subjects: 45
Study 19515265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention via telephone follow-up (n = 288)
Number of subjects: 568
Study 19515265 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 280)
Number of subjects: 568
Study 17342994 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinhartdt and sea cucumber capsule (RSC) combined with Donepezil
Number of subjects: 68
Study 17342994 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 68
Study 17342994 — intervention group
Group type: COMPARATOR
Intervention: Reinhartdt and sea cucumber capsule (RSC)
Number of subjects: 68
Study 15509080 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% Triclosan, 1,000ppm fluoride and 0.13% calcium glycerophosphate in a natural calcium carbonate base
Number of subjects: 0
Study 15509080 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.2% Triclosan and 1,000ppm fluoride in a precipitated calcium carbonate base
Number of subjects: 0
Study 15509080 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% Triclosan, 1,000ppm fluoride and Gantrez in a silica base
Number of subjects: 0
Study 15509080 — intervention group
Group type: COMPARATOR
Intervention: Commercially available toothpastes without the above actives
Number of subjects: 0
Study 11673815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 200 mg bid + saquinavir 600 mg bid (Rito-Saq)
Number of subjects: 31
Study 11673815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 1,000 mg bid + saquinavir 600 mg bid (Nelf-Saq)
Number of subjects: 31
Study 11673815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelf-Saq and Rito-Saq
Number of subjects: 31
Study 9065232 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-Service (FFS)
Number of subjects: 0
Study 9065232 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Case Management (PCCM)
Number of subjects: 0
Study 9065232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 7699617 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 64
Study 7699617 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 64
Study 7699617 — intervention group
Group type: COMPARATOR
Intervention: Both MTX and AZA
Number of subjects: 64
Study 3197710 — intervention group
Group type: EXPERIMENTAL
Intervention: FDDF oral administration of lorazepam 4 mg
Number of subjects: 16
Study 3197710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of lorazepam 4 mg
Number of subjects: 16
Study 3197710 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both formulations
Number of subjects: 16
Study 30030579 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight-bearing from day 1
Number of subjects: 60
Study 30030579 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing for 6 weeks (Control)
Number of subjects: 60
Study 25450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss plus exercise (D + E)
Number of subjects: 450
Study 25450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss-only (D)
Number of subjects: 450
Study 25450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only (E)
Number of subjects: 450
Study 23175178 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG) - performed 10 headers at 11.2 m/s in 10 min
Number of subjects: 0
Study 23175178 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - simulated headers
Number of subjects: 0
Study 21546878 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 21546878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21546878 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Rosuvastatin and Placebo
Number of subjects: 0
Study 18579216 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400-800 mg/day) plus lithium/divalproex
Number of subjects: 0
Study 18579216 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lithium/divalproex
Number of subjects: 0
Study 17123184 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb interval-training program combined with a general rehabilitation program
Number of subjects: 14
Study 17123184 — intervention group
Group type: COMPARATOR
Intervention: General rehabilitation program
Number of subjects: 14
Study 17123184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (training and control)
Number of subjects: 14
Study 12885680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 12885680 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin sodium
Number of subjects: 427
Study 12885680 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg enoxaparin
Number of subjects: 427
Study 12885680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenoxicam
Number of subjects: 427
Study 10558945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (single-dose)
Number of subjects: 245
Study 10558945 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (7-day course)
Number of subjects: 245
Study 10558945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 245
Study 10558945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Erythromycin
Number of subjects: 245
Study 8914204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen in combination with chemotherapy for metastatic melanoma
Number of subjects: 0
Study 8914204 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate as an adjuvant
Number of subjects: 0
Study 8914204 — intervention group
Group type: COMPARATOR
Intervention: Steroid hormones
Number of subjects: 0
Study 1677820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium (PIP), 0.10 mg/kg
Number of subjects: 82
Study 1677820 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (V), 0.12 mg/kg
Number of subjects: 82
Study 6340546 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic adhesive moisture vapor permeable (SAM) dressings
Number of subjects: 60
Study 6340546 — intervention group
Group type: COMPARATOR
Intervention: Fine mesh gauze dressings
Number of subjects: 60
Study 6340546 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm
Number of subjects: 60
Study 6340546 — intervention group
Group type: COMPARATOR
Intervention: Op-Site
Number of subjects: 60
Study 30765403 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial and machine learning analysis of structural heart disease
Number of subjects: 2400
Study 30765403 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of a detailed cardiovascular map and predictive machine learning system
Number of subjects: 2400
Study 30448030 — intervention group
Group type: EXPERIMENTAL
Intervention: TURBT plus immediate postoperative epirubicin (50 mg)
Number of subjects: 236
Study 30448030 — intervention group
Group type: COMPARATOR
Intervention: TURBT alone (control group)
Number of subjects: 236
Study 28070882 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 180 mg ticagrelor pre-PCI, followed by ticagrelor 90 mg twice daily post-PCI (group TT)
Number of subjects: 77
Study 28070882 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of ticagrelor 90 mg twice daily (group CT)
Number of subjects: 77
Study 28070882 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily post-PCI (group CC)
Number of subjects: 77
Study 28070882 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of ticagrelor (group TT)
Number of subjects: 77
Study 28070882 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregation measurement in a separate cohort (diabetic and non-diabetic patients)
Number of subjects: 77
Study 25111795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation for 4 hours
Number of subjects: 12
Study 25111795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation for 6 hours
Number of subjects: 12
Study 25111795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation for 2 hours
Number of subjects: 12
Study 25606328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT) and splinting
Number of subjects: 50
Study 25606328 — intervention group
Group type: COMPARATOR
Intervention: Sham LLLT and splinting
Number of subjects: 50
Study 25606328 — intervention group
Group type: COMPARATOR
Intervention: Only splints
Number of subjects: 50
Study 21981745 — intervention group
Group type: EXPERIMENTAL
Intervention: Media campaign with culturally sensitive educational material
Number of subjects: 1052
Study 19826937 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation for 12 weeks
Number of subjects: 40
Study 19826937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17402468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mounted condition
Number of subjects: 10
Study 17402468 — intervention group
Group type: COMPARATOR
Intervention: Harnessed condition
Number of subjects: 10
Study 15605971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequinol 2%/tretinoin 0.01%
Number of subjects: 216
Study 15605971 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone 3%
Number of subjects: 216
Study 11480450 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner letter
Number of subjects: 6133
Study 11480450 — intervention group
Group type: EXPERIMENTAL
Intervention: Flag in women's notes prompting discussion by health professionals
Number of subjects: 6133
Study 11480450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 6133
Study 11480450 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 6133
Study 9629829 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive telephone prompts by a medical peer
Number of subjects: 4
Study 9629829 — intervention group
Group type: EXPERIMENTAL
Intervention: Embossed pen with the questionnaire
Number of subjects: 4
Study 9629829 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance letter prompt
Number of subjects: 4
Study 9629829 — intervention group
Group type: EXPERIMENTAL
Intervention: Single attempt advance telephone prompt by a non-medical research assistant
Number of subjects: 4
Study 9629829 — intervention group
Group type: COMPARATOR
Intervention: Overall response rates
Number of subjects: 4
Study 9629829 — intervention group
Group type: COMPARATOR
Intervention: Male GPs
Number of subjects: 4
Study 9629829 — intervention group
Group type: COMPARATOR
Intervention: Female GPs
Number of subjects: 4
Study 7931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 35
Study 7931040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 3144366 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 1695
Study 3144366 — intervention group
Group type: COMPARATOR
Intervention: Physiological management
Number of subjects: 1695
Study 31662030 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Cisplatin/Vinorelbine (ACT)
Number of subjects: 0
Study 31662030 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy or surgery only (based on model recommendation)
Number of subjects: 0
Study 31662030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients receiving ACT
Number of subjects: 0
Study 30646158 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN) initiated after 1 week
Number of subjects: 289
Study 30646158 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN) initiated within 24 hours
Number of subjects: 289
Study 26820239 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan dentifrice
Number of subjects: 30
Study 26820239 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 30
Study 24876615 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM real time
Number of subjects: 41
Study 23342329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressed PCRs (IPS e.max-Press, Ivoclar Vivadent)
Number of subjects: 25
Study 23342329 — intervention group
Group type: COMPARATOR
Intervention: CAD/CAM PCRs (ProCAD, Ivoclar Vivadent)
Number of subjects: 25
Study 21557868 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition A - cooked carrots, pasta and chicken
Number of subjects: 98